Stereotactic Radiotherapy for Renal Cell Carcinoma: The Fallacy of (False) Positive Post-treatment Biopsy?

Affiliations

¹ Department of Oncology, London Health Sciences Centre and Western University, London, Canada.
² Cabrini Department of Surgery, Monash University, Melbourne, Australia; Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
³ Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. Electronic address: shankar.siva@petermac.org.

Editorial

Rohann J M Correa et al. Eur Urol. 2023 Sep.

. 2023 Sep;84(3):287-288.

doi: 10.1016/j.eururo.2023.03.025. Epub 2023 Apr 7.

¹ Department of Oncology, London Health Sciences Centre and Western University, London, Canada.
² Cabrini Department of Surgery, Monash University, Melbourne, Australia; Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
³ Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. Electronic address: shankar.siva@petermac.org.

No abstract available

Comment on

Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer.
Hannan R, McLaughlin MF, Pop LM, Pedrosa I, Kapur P, Garant A, Ahn C, Christie A, Zhu J, Wang T, Robles L, Durakoglugil D, Woldu S, Margulis V, Gahan J, Brugarolas J, Timmerman R, Cadeddu J. Hannan R, et al. Eur Urol. 2023 Sep;84(3):275-286. doi: 10.1016/j.eururo.2023.02.016. Epub 2023 Mar 8. Eur Urol. 2023. PMID: 36898872 Free PMC article. Clinical Trial.